Zimbabwe has turned down a significant American healthcare agreement valued at 367 million US dollars (272 million pounds) over five years over Washington's insistence on confidential biological samples.
This rejection came to light following a government memo from December was disclosed, which showed Head of State Emmerson Mnangagwa deemed the arrangement was "lopsided".
A government spokesman has since stated that the United States was demanding access to health data for scientific study and commercial gain but was not willing to share the resulting advantages from future vaccines.
"We must now begin the difficult and regrettable process of scaling back our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the United States had provided over $1.9bn in health funding to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has urged continued negotiations to find a deal acceptable to both sides so the nation's vital HIV treatment initiative can continue.
Wider Background
This development follows a comparable case in Kenya, where a court suspended a related health funding agreement after concerns were filed about the safety of Kenyans' medical information.
After resuming office recently, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
USAID had administered assistance for the American government, but Trump argued its expenditure was "inefficient" and his government was pursuing direct bilateral agreements to enhance transparency and responsibility.
Based on reports, 16 nations in Africa have so far signed similar agreements, constituting over $18.3bn in committed funds.
Specifics of the Rejected Agreement
The money for Zimbabwe would have gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this cooperation could have provided extraordinary benefits for Zimbabwean communities, particularly the 1.2 million currently on HIV treatment through US-supported initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana argued the proposed deal was "unequal".
"Zimbabwe was being asked to provide its genetic material and health information over an extended period, with no equivalent assurance of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that could result from that provided information," his statement read.
"Effectively, our country would supply the raw materials for scientific discovery with no certainty that the resulting innovations would be accessible to our population if a new disease outbreak arise."
National Interest and International Frameworks
He also pointed out that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were disrupting systems already established via the global organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework created to deal with future pandemics.
"This framework is designed to guarantee that when a country provides its data, the benefits – including vaccines and treatments – are shared equitably, not monopolised solely by those with the capability to create them."
These objections regarding the US deal "should not be misconstrued as anti-American sentiment," he added.
"We are open to ongoing dialogue with our American counterparts on how subsequent collaboration might be arranged in a manner that respects the sovereignty and interests of each country."
Medical Community Reaction
Medical experts expressed it recognised the government's concerns, but urged that talks should continue considering a large portion of the country's Aids initiatives depended on external financing.
"If technical issues arise, including those involving data governance or agreement terms, these can often be resolved via detailed discussion and negotiated safeguards," it said.
This impasse highlights the complex challenges between accepting crucial foreign assistance and protecting a country's data in an increasingly data-driven world.